Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis: Genetic and Physiological Evidence

Circulation

Volumn 108, Issue 24, 2003, Pages 3042-3047

  Dayoub, Hayan ^a   Achan, Vinod ^b   Adimoolam, Shanthi ^a   Jacobi, Johannes ^a   Stuehlinger, Marcus C ^a   Wang, Bing Yin ^a   Tsao, Philip S ^a   Kimoto, M ^c   Vallance, Patrick ^b   Patterson, Andrew J ^a   Cooke, John P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c OKAYAMA PREFECTURAL UNIVERSITY   (Japan)

Author keywords

Blood pressure; Endothelium; Nitric oxide; Risk factors; Vasodilation

Indexed keywords

ARGININE METHYL ESTER; DIMETHYLARGININASE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROGEN OXIDE;

ADOLESCENT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GENE OVEREXPRESSION; GENE TRANSFER; HEART MUSCLE CONTRACTILITY; HEART STROKE VOLUME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SYNTHESIS; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE; TRANSGENICS; URINE LEVEL;

AMIDOHYDROLASES; ANIMALS; ARGININE; CELLS, CULTURED; ENDOTHELIUM; HEMODYNAMIC PROCESSES; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TRANSFECTION;

EID: 0346365087     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000101924.04515.2E     Document Type: Article

References (44)

1. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141-1146.
2. Tsao PS, Cooke JP. Endothelial alterations in hypercholesterolemia: more than simply vasodilator dysfunction. J Cardiovasc Pharmacol. 1998;32: S48-S53.
3. Goonasekera CD, Rees DD, Woolard P, et al. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997;15:901-909.
4. Goonasekera CD, Shah V, Rees DD, et al. Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma? Blood Press. 2000;9:16-21.
5. Lundman P, Eriksson MJ, Stuhlinger M, et al. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol. 2001;38:111-116.
6. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998;98:1842-1847.
7. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420-1426.
8. Abbasi F, Asagmi T, Cooke JP. et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 2001;88:1201-1203.
9. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 2001;158:425-430.
10. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113-2117.
11. Vallance P, Leone A, Calver A. et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
12. Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand. 1998;77:808-813.
13. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127-2128.
14. MacAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol. 1996;119:1533-1540.
15. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-3095.
16. Stuhlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104:2569-2575.
17. Lin K, Ito A, Asagami T, et al. Dysregulation of dimethylarginine dimethylaminohydrolase: a mechanism for endothelial dysfunction in diabetes mellitus. Circulation. 2002:106:987-992.
18. Achan V, Tran CT, Arrigoni F, et al. All-trans-retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res. 2002;90:764-769.
19. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343:209-214.
20. Wilson BD, Ollmann MM, Kang L, et al. Structure and function of ASP, the human homolog of the mouse agouti gene. Hum Mol Genet. 1995;4:223-230.
21. Krege JH, Hodgin JB, Hagaman JR, et al. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995;25:1111-1115.
22. Boger RH, Bode-Boger SM, Tsao PS, et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol. 2000;36:2287-2295.
23. Marzinzig M, Nussler AK, Stadler J, et al. Improved methods to measure end products of nitric oxide in biological fluids: nitrite, nitrate, and S-nitrosothiols. Nitric Oxide 1997;1:177-189.
24. Stamler J, Mendelsohn ME, Amarante P, et al. N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res. 1989;65:789-795.
25. Theilmeier G, Chan JR, Zalpour C, et al. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler Thromb Vasc Biol. 1997;17:3557-3564.
26. Wolf A, Zalpour C, Theilmeier G, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol. 1997;29:479-485.
27. Tsao PS, Buitrago R, Chan JR, et al. Fluid flow inhibits endothelial adhesiveness: nitric oxide and transcriptional regulation of VCAM-1. Circulation. 1996:94:1682-1689.
28. Tsao PS, Wang B, Buitrago R, et al. Nitric oxide regulates monocyte chemotactic protein-1. Circulation. 1997;96:934-940.
29. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 1995;92:1137-1141.
30. Cooke JP, Singer AH, Tsao P, et al. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 1992;90:1168-1172.
31. Tsao PS, McEvoy LM, Drexler H, et al. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation. 1994;89:2176-2182.
32. Candipan RC, Wang BY, Buitrago R, et al. Regression or progression: dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol. 1996;16:44-50.
33. Kojda G, Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res. 1999;41:514-523.
34. Balligand JL, Kelly RA, Marsden PA, et al. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA. 1993;90:347-351.
35. Keaney JF Jr, Hare JM, Balligand JL, et al. Inhibition of nitric oxide synthase augments myocardial contractile responses to beta-adrenergic stimulation. Am J Physiol. 1996;271:H2646-H2652.
36. Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 1996;93:1087-1094.
37. Vejlstrup NG, Bouloumie A, Boesgaard S, et al. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol 1998;30:1215-1223.
38. Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther. 2000;86:49-86.
39. Nishida Y, Chen QH, Tandai-Hiruma M, et al. Neuronal nitric oxide strongly suppresses sympathetic outflow in high-salt Dahl rats. J Hypertens. 2001;19:627-634.
40. Sears CE, Choate JK, Paterson DJ. Effect of nitric oxide synthase inhibition on the sympatho-vagal control of heart rate. J Auton Nerv Syst. 1998;73:63-73.
41. Zanzinger J, Czachurski J, Seller H. Neuronal nitric oxide reduces sympathetic excitability by modulation of central glutamate effects in pigs. Circ Res. 1997;80:565-571.
42. Cooke JP, Rossitch E, Andon N, et al. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest. 1991;88:1663-1671.
43. Leiper J, Murray-Rust J, McDonald N, et al. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA. 2002;99:13527-13532.
44. Li G, Regunathan S, Barrow CJ, et al. Agmatine: an endogenous clonidine-displacing substance in the brain. Science. 1994;263:966-969.